Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation

Yvett Sosa, Roman Deniskin, I. J. Frame, Matthew S. Steiginga, Deepak Bandyopadhyay, Todd L. Graybill, Lorena A. Kallal, Michael T. Ouellette, Andrew J. Pope, Katherine L. Widdowson, Robert J. Young, Myles Akabas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Emerging resistance to current antimalarial medicines underscores the importance of identifying new drug targets and novel compounds. Malaria parasites are purine auxotrophic and import purines via the Plasmodium falciparum equilibrative nucleoside transporter type 1 (PfENT1). We previously showed that PfENT1 inhibitors block parasite proliferation in culture. Our goal was to identify additional, possibly more optimal chemical starting points for a drug discovery campaign. We performed a high throughput screen (HTS) of GlaxoSmithKline's 1.8 million compound library with a yeast-based assay to identify PfENT1 inhibitors. We used a parallel progression strategy for hit validation and expansion, with an emphasis on chemical properties in addition to potency. In one arm, the most active hits were tested for human cell toxicity; 201 had minimal toxicity. The second arm, hit expansion, used a scaffold-based substructure search with the HTS hits as templates to identify over 2000 compounds; 123 compounds had activity. Of these 324 compounds, 175 compounds inhibited proliferation of P. falciparum parasite strain 3D7 with IC50 values between 0.8 and ∼180 μM. One hundred forty-two compounds inhibited PfENT1 knockout (pfent1Δ) parasite growth, indicating they also hit secondary targets. Thirty-two hits inhibited growth of 3D7 but not pfent1Δparasites. Thus, PfENT1 inhibition was sufficient to block parasite proliferation. Therefore, PfENT1 may be a viable target for antimalarial drug development. Six compounds with novel chemical scaffolds were extensively characterized in yeast-, parasite-, and human-erythrocyte-based assays. The inhibitors showed similar potencies against drug sensitive and resistant P. falciparum strains. They represent attractive starting points for development of novel antimalarial drugs.

Original languageEnglish (US)
JournalACS Infectious Diseases
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Equilibrative Nucleoside Transporter 1
Plasmodium falciparum
Malaria
Parasites
Antimalarials
Yeasts
Purines
purine
Drug Discovery
Growth
Pharmaceutical Preparations
Inhibitory Concentration 50
Libraries
Erythrocytes

Keywords

  • drug discovery
  • high throughput screen
  • malaria
  • purine
  • transporter

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation. / Sosa, Yvett; Deniskin, Roman; Frame, I. J.; Steiginga, Matthew S.; Bandyopadhyay, Deepak; Graybill, Todd L.; Kallal, Lorena A.; Ouellette, Michael T.; Pope, Andrew J.; Widdowson, Katherine L.; Young, Robert J.; Akabas, Myles.

In: ACS Infectious Diseases, 01.01.2019.

Research output: Contribution to journalArticle

Sosa, Yvett ; Deniskin, Roman ; Frame, I. J. ; Steiginga, Matthew S. ; Bandyopadhyay, Deepak ; Graybill, Todd L. ; Kallal, Lorena A. ; Ouellette, Michael T. ; Pope, Andrew J. ; Widdowson, Katherine L. ; Young, Robert J. ; Akabas, Myles. / Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation. In: ACS Infectious Diseases. 2019.
@article{77f98e5f46fb4b9c9eaae843498d7b80,
title = "Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation",
abstract = "Emerging resistance to current antimalarial medicines underscores the importance of identifying new drug targets and novel compounds. Malaria parasites are purine auxotrophic and import purines via the Plasmodium falciparum equilibrative nucleoside transporter type 1 (PfENT1). We previously showed that PfENT1 inhibitors block parasite proliferation in culture. Our goal was to identify additional, possibly more optimal chemical starting points for a drug discovery campaign. We performed a high throughput screen (HTS) of GlaxoSmithKline's 1.8 million compound library with a yeast-based assay to identify PfENT1 inhibitors. We used a parallel progression strategy for hit validation and expansion, with an emphasis on chemical properties in addition to potency. In one arm, the most active hits were tested for human cell toxicity; 201 had minimal toxicity. The second arm, hit expansion, used a scaffold-based substructure search with the HTS hits as templates to identify over 2000 compounds; 123 compounds had activity. Of these 324 compounds, 175 compounds inhibited proliferation of P. falciparum parasite strain 3D7 with IC50 values between 0.8 and ∼180 μM. One hundred forty-two compounds inhibited PfENT1 knockout (pfent1Δ) parasite growth, indicating they also hit secondary targets. Thirty-two hits inhibited growth of 3D7 but not pfent1Δparasites. Thus, PfENT1 inhibition was sufficient to block parasite proliferation. Therefore, PfENT1 may be a viable target for antimalarial drug development. Six compounds with novel chemical scaffolds were extensively characterized in yeast-, parasite-, and human-erythrocyte-based assays. The inhibitors showed similar potencies against drug sensitive and resistant P. falciparum strains. They represent attractive starting points for development of novel antimalarial drugs.",
keywords = "drug discovery, high throughput screen, malaria, purine, transporter",
author = "Yvett Sosa and Roman Deniskin and Frame, {I. J.} and Steiginga, {Matthew S.} and Deepak Bandyopadhyay and Graybill, {Todd L.} and Kallal, {Lorena A.} and Ouellette, {Michael T.} and Pope, {Andrew J.} and Widdowson, {Katherine L.} and Young, {Robert J.} and Myles Akabas",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acsinfecdis.9b00168",
language = "English (US)",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation

AU - Sosa, Yvett

AU - Deniskin, Roman

AU - Frame, I. J.

AU - Steiginga, Matthew S.

AU - Bandyopadhyay, Deepak

AU - Graybill, Todd L.

AU - Kallal, Lorena A.

AU - Ouellette, Michael T.

AU - Pope, Andrew J.

AU - Widdowson, Katherine L.

AU - Young, Robert J.

AU - Akabas, Myles

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Emerging resistance to current antimalarial medicines underscores the importance of identifying new drug targets and novel compounds. Malaria parasites are purine auxotrophic and import purines via the Plasmodium falciparum equilibrative nucleoside transporter type 1 (PfENT1). We previously showed that PfENT1 inhibitors block parasite proliferation in culture. Our goal was to identify additional, possibly more optimal chemical starting points for a drug discovery campaign. We performed a high throughput screen (HTS) of GlaxoSmithKline's 1.8 million compound library with a yeast-based assay to identify PfENT1 inhibitors. We used a parallel progression strategy for hit validation and expansion, with an emphasis on chemical properties in addition to potency. In one arm, the most active hits were tested for human cell toxicity; 201 had minimal toxicity. The second arm, hit expansion, used a scaffold-based substructure search with the HTS hits as templates to identify over 2000 compounds; 123 compounds had activity. Of these 324 compounds, 175 compounds inhibited proliferation of P. falciparum parasite strain 3D7 with IC50 values between 0.8 and ∼180 μM. One hundred forty-two compounds inhibited PfENT1 knockout (pfent1Δ) parasite growth, indicating they also hit secondary targets. Thirty-two hits inhibited growth of 3D7 but not pfent1Δparasites. Thus, PfENT1 inhibition was sufficient to block parasite proliferation. Therefore, PfENT1 may be a viable target for antimalarial drug development. Six compounds with novel chemical scaffolds were extensively characterized in yeast-, parasite-, and human-erythrocyte-based assays. The inhibitors showed similar potencies against drug sensitive and resistant P. falciparum strains. They represent attractive starting points for development of novel antimalarial drugs.

AB - Emerging resistance to current antimalarial medicines underscores the importance of identifying new drug targets and novel compounds. Malaria parasites are purine auxotrophic and import purines via the Plasmodium falciparum equilibrative nucleoside transporter type 1 (PfENT1). We previously showed that PfENT1 inhibitors block parasite proliferation in culture. Our goal was to identify additional, possibly more optimal chemical starting points for a drug discovery campaign. We performed a high throughput screen (HTS) of GlaxoSmithKline's 1.8 million compound library with a yeast-based assay to identify PfENT1 inhibitors. We used a parallel progression strategy for hit validation and expansion, with an emphasis on chemical properties in addition to potency. In one arm, the most active hits were tested for human cell toxicity; 201 had minimal toxicity. The second arm, hit expansion, used a scaffold-based substructure search with the HTS hits as templates to identify over 2000 compounds; 123 compounds had activity. Of these 324 compounds, 175 compounds inhibited proliferation of P. falciparum parasite strain 3D7 with IC50 values between 0.8 and ∼180 μM. One hundred forty-two compounds inhibited PfENT1 knockout (pfent1Δ) parasite growth, indicating they also hit secondary targets. Thirty-two hits inhibited growth of 3D7 but not pfent1Δparasites. Thus, PfENT1 inhibition was sufficient to block parasite proliferation. Therefore, PfENT1 may be a viable target for antimalarial drug development. Six compounds with novel chemical scaffolds were extensively characterized in yeast-, parasite-, and human-erythrocyte-based assays. The inhibitors showed similar potencies against drug sensitive and resistant P. falciparum strains. They represent attractive starting points for development of novel antimalarial drugs.

KW - drug discovery

KW - high throughput screen

KW - malaria

KW - purine

KW - transporter

UR - http://www.scopus.com/inward/record.url?scp=85071663557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071663557&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.9b00168

DO - 10.1021/acsinfecdis.9b00168

M3 - Article

C2 - 31373203

AN - SCOPUS:85071663557

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

ER -